NeOnc Technologies Reports Positive Topline Data Of NEO100 Phase 2a Study, Stock Up In Pre-Market
NeOnc Technologies Holdings (NTHI) reported positive topline Phase 2a results for intranasal NEO100 (NEO100-01) in IDH1-mutant Grade IV glioma or Grade III astrocytoma. In 24 patients at 1,152 mg/day, six-month progression-free survival was 48.9% vs 20% expected. Median overall survival was 26.09 months. Company plans an FDA Type B meeting and will present full safety data.
How this was made
The 30-second read
Why it matters
The disclosed 6-month progression-free survival and overall survival metrics, plus intent to seek an FDA Type B meeting, can shift perceived probability of regulatory advancement and financing appetite.
Market read
Traders are reacting to newly disclosed Phase 2a efficacy versus a pre-specified benchmark and a near-term regulatory-planning catalyst.
What to watch
The article does not provide safety/tolerability specifics or statistical context beyond the primary endpoint comparison, and the registrational path depends on the upcoming FDA Type B meeting.
Background
NeOnc is evaluating intranasal NEO100 (NEO100-01) in IDH1-mutant recurrent or progressive Grade IV glioma and Grade III astrocytoma.
Ticker impact
NeOnc reported positive Phase 2a topline results for NEO100-01, with 6-month PFS 48.9% vs 20% pre-specified expectation.
Likely continued pre-market and early-session bid, with follow-through dependent on full dataset quality and FDA Type B meeting outcomes.
The article discloses multiple efficacy endpoints (PFS and OS) plus a planned FDA Type B meeting, which are actionable catalysts for biotech risk repricing, though it is topline and safety details are pending.
Market effects
Adds incremental evidence for intranasal IDH1-mutant high-grade glioma therapies, potentially improving sentiment toward similar neuro-oncology programs.
Limited, primarily US small-cap biotech sentiment given the Nasdaq pre-market move.
Moderate for global biotech risk appetite in neuro-oncology, but not a broad cross-market catalyst.
Counterpoint
Topline Phase 2a results can overstate durability; without full safety and dataset details, the market may fade gains if adverse events or subgroup effects are less favorable.
Key entities
- companyNeOnc Technologies Holdings, Inc.
Reported positive Phase 2a topline results for NEO100-01 and plans an FDA Type B meeting to align on a registrational development path.
- clinical_programNEO100-01 (NEO100 Phase 2a)
Intranasal NEO100 study in IDH1-mutant high-grade glioma, with 24 patients treated at 1,152 mg/day.
- regulatorU.S. Food and Drug Administration (FDA)
Company intends to request a Type B meeting to align on a registrational development path.
